Sarepta Sells Arrowhead Stake to Fund Milestone Payment
Sarepta sells $174M in Arrowhead shares to fund a $100M milestone payment as part of its RNAi drug collaboration.
Small caps rally as Magnificent 7 stocks roll over in market rotation
Investors rotated to small companies and turned away from megacap technology stocks that have led the market in recent years.
Arrowhead ( ARWR ) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.Thursday, August 7, 2025 at 8:30 p.m. ETPresident and Chief Executive Officer - Dr. Christopher AnzaloneContinue reading ...
Arrowhead ( ARWR ) Q3 Revenue Drops 41%
Arrowhead Pharmaceuticals ( NASDAQ:ARWR ) , a biotechnology firm focused on developing RNA interference ( RNAi ) therapeutics, released its fiscal third-quarter earnings on August 7, 2025. The most notable news from the release was a substantial miss on both GAAP revenue and earnings for Q3 ...
Sarepta Soars on Q2 Earnings & Sales Beat, Resumes Elevidys Deliveries
SRPT rallies after Q2 earnings and revenue beat expectations as Elevidys deliveries resume following FDA clearance.
Sarepta to Report Q2 Earnings: What's in Store for the Stock?
SRPT's Q2 report, set to arrive Aug. 6, is likely to have Elevidys updates, restructuring plans and sales outlook in sharp investor focus.
Sarepta Therapeutics Surges Over 40% In Tuesday Pre-Market: What's Going On? - Arrowhead Pharma ( NASDAQ:ARWR ) , Sarepta Therapeutics ( NASDAQ:SRPT )
Stock of Sarepta Therapeutics Inc. SRPT surged 41.05% in Tuesday pre-market following the U.S. Food and Drug Administration's ( FDA ) recommendation to lift the voluntary hold on Elevidys, Sarepta's gene therapy for Duchenne Muscular Dystrophy.
FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys - Sarepta Therapeutics ( NASDAQ:SRPT )
FDA is probing the death of an 8-year-old who received Sarepta's Elevidys for Duchenne muscular dystrophy. The death was deemed unrelated to the gene therapy, but product distribution has been voluntarily suspended. Missed the rally? Learn exactly where the next leaders are emerging here. The ...
Sarepta Gets Thumbs Down From Regulators Regarding Gene Therapy - Sarepta Therapeutics ( NASDAQ:SRPT )
CHMP issued a negative opinion on Elevidys for Duchenne patients aged 3-7 despite secondary gains in motor function. Elevidys has treated over 900 DMD patients, but EMA and FDA raise concerns over efficacy and safety data. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On
GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday - Arrowhead Pharma ( NASDAQ:ARWR ) , Abivax ( NASDAQ:ABVX )
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Wednesday. Shares of GE Vernova Inc. GEV rose sharply during Wednesday's session after the company posted better-than-expected second-quarter 2025 earnings and raised its full-year guidance.
SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny
Sarepta stock down as it halts U.S. Elevidys shipments after FDA pressure and safety concerns tied to patient deaths due to liver failure.
Sarepta Pauses Elevidys Shipments Amid FDA Safety Review - Sarepta Therapeutics ( NASDAQ:SRPT )
Sarepta paused all Elevidys shipments to align with FDA safety label requests. Elevidys 2025 revenue now forecast at $795.7 million, with Q2 contribution of $282 million. A new wave of value and momentum stocks could be setting up for major moves-and Tim Melvin will name them live this Wednesday.
SRPT Down After Third Death in Muscular Dystrophy Gene Therapy Program
Sarepta plummets after a third death in its muscular dystrophy program for investigational gene therapies, prompts FDA action and intensifies safety scrutiny.
SRPT Stock Soars on Unveiling New Restructuring Plan, Pipeline Pivots
Sarepta's shares jump after unveiling a major restructuring plan to cut costs. The company shifts focus to siRNA and reprioritizes its pipeline.
Cramer Wonders If Arrowhead Pharmaceuticals Has 'The Horses' - Arrowhead Pharma ( NASDAQ:ARWR ) , Dover ( NYSE:DOV )
Fluor is "always a bridesmaid, never a bride," Cramer says. Ready to turn the market's comeback into steady cash flow? Grab the top 3 stocks to buy right here. On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Dover Corporation DOV.
Why Coinbase Global Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Arrowhead Pharma ( NASDAQ:ARWR ) , Accelerate Diagnostics ( NASDAQ:AXDX )
Shares of Coinbase Global, Inc. COIN rose sharply in today's pre-market trading. Coinbase is set to join the S&P 500, replacing Discover Financial Services DFS in the benchmark index, according to a Monday announcement.
Why Coinbase Global Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Arrowhead Pharma ( NASDAQ:ARWR ) , Accelerate Diagnostics ( NASDAQ:AXDX )
Shares of Coinbase Global, Inc. COIN rose sharply in today's pre-market trading. Coinbase is set to join the S&P 500, replacing Discover Financial Services DFS in the benchmark index, according to a Monday announcement.
SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut
SRPT reports mixed first-quarter 2025 results. The stock plunges after the company significantly lowers its 2025 sales guidance.
Oncotelic's ASO Platform Could Mark A New Era In RNA Therapeutics - Oncotelic Therapeutics ( OTC:OTLC )
Oncotelic Therapeutics Inc. OTLC, the RNA-based therapeutics company, says it is making progress advancing its antisense oligonucleotide ( ASO ) platform, fueled by promising clinical data and growing evidence that Transforming Growth Factor Beta 2 ( TGFB2 ) may be a critical driver of immune ...
How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion
We advise investors with a long-term horizon to remain invested in Sarepta stock, given its encouraging commercial portfolio and robust pipeline potential.
RNA Therapeutics Market is expected to generate a revenue of USD 22.37 Billion by 2032, Globally, at 9.4% CAGR: Verified Market Research®
Lewes, Delaware, March 17, 2025 ( GLOBE NEWSWIRE ) -- The Global RNA Therapeutics Market Size is projected to grow at a CAGR of 9.4% from 2026 to 2032, according to a new report published by Verified Market Research®.
Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases - Arrowhead Pharma ( NASDAQ:ARWR )
ARO-C3 showed a maximum mean C3 reduction of 89% and sustained reduction over 87% through 24 weeks in a Phase 1/2 study. The therapy reduced proteinuria, with a mean UPCR drop of 41% and a maximum individual reduction of 89%. Find out which stock just claimed the top spot in the new Benzinga ...
Sarepta Q4 Earnings Lag Estimates, Revenues Gain on Gene Therapy Sales
SRPT reports mixed fourth-quarter 2024 results. It closes the multi-billion-dollar deal with Arrowhead and adds four new clinical programs to its pipeline.
Genelux Corporation Announces New Chief Financial Officer - Genelux ( NASDAQ:GNLX )
WESTLAKE VILLAGE, Calif., Feb. 03, 2025 ( GLOBE NEWSWIRE ) -- Genelux Corporation GNLX, a late clinical-stage immuno-oncology company, today announced that Matthew Pulisic has joined the company as its new Chief Financial Officer, effective January 30, 2025.
Genelux Corporation Announces New Chief Financial Officer
WESTLAKE VILLAGE, Calif., Feb. 03, 2025 ( GLOBE NEWSWIRE ) -- Genelux Corporation ( NASDAQ: GNLX ) , a late clinical-stage immuno-oncology company, today announced that Matthew Pulisic has joined the company as its new Chief Financial Officer, effective January 30, 2025.
Guidewire Software ( GWRE ) Surges 11.5%: Is This an Indication of Further Gains?
Guidewire Software (GWRE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Knight-Swift Transportation Posts Upbeat Earnings, Joins TAL Education, LSI Industries, GE Aerospace And Other Big Stocks Moving Higher On Thursday - Evolv Technologies ( NASDAQ:EVLV ) , Blaize Holdings ( NASDAQ:BZAI )
U.S. stocks were mixed, with the Dow Jones index gaining around 100 points on Thursday. Shares of Knight-Swift Transportation Holdings Inc. KNX rose sharply during Thursday's session as the company reported better-than-expected fourth-quarter adjusted earnings results.
Top 3 Tech Stocks That Are Ticking Portfolio Bombs - Guidewire Software ( NYSE:GWRE ) , Himax Techs ( NASDAQ:HIMX )
As of Jan. 23, 2025, three stocks in the information technology sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on ...
SRPT Stock Rises 23% in a Year: Time to Buy, Hold or Sell?
The upside in Sarepta's share price can be attributed to the encouraging sales performance of its DMD gene therapy, which has demonstrated blockbuster potential.
Sarepta Therapeutics Stock Surges 43% YTD: How to Play the Stock?
The rise in SRPT's share price can be attributed to the encouraging sales performance of its recently approved one-shot gene therapy for DMD.
SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene Therapies
Sarepta in-licenses rights to four clinical-stage and three preclinical-stage programs targeting muscle, central nervous system and rare pulmonary disorders.
J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday - Arrowhead Pharma ( NASDAQ:ARWR ) , Embecta ( NASDAQ:EMBC )
U.S. stocks were mixed, with the Dow Jones index falling more than 200 points on Tuesday. Shares of The J. M. Smucker Company SJM rose sharply during Tuesday's session after the company reported better-than-expected second-quarter financial results and raised its FY25 adjusted EPS guidance with ...
Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs - Tempest Therapeutics ( NASDAQ:TPST )
BRISBANE, Calif., Sept. 18, 2024 ( GLOBE NEWSWIRE ) -- Tempest Therapeutics, Inc. TPST, a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced the appointment of Sheldon Mullins as Vice President, Regulatory ...
Arrowhead Pharmaceuticals ( NASDAQ:ARWR ) Upgraded at StockNews.com
Arrowhead Pharmaceuticals ( NASDAQ:ARWR - Get Free Report ) was upgraded by StockNews.com to a "sell" rating in a research report issued on Tuesday. A number of other equities analysts also recently issued reports on the company.
S&P Global To Rally More Than 13%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. • Truist Securities raised the price target for Belden Inc. ( NYSE:BDC ) from $119 to $123.
S&P Global To Rally More Than 13%? Here Are 10 Top Analyst Forecasts For Friday - S&P Global ( NYSE:SPGI )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Truist Securities raised the price target for Belden Inc. BDC from $119 to $123.
Why Arrowhead Pharmaceuticals ( ARWR ) Stock Is Seeing Blue Skies - Arrowhead Pharma ( NASDAQ:ARWR )
Arrowhead Pharmaceuticals Inc ARWR shares were trading higher by 6% to $27.54 during Monday's session after the company announced that it presented preclinical data on ARO-INHBE at the American Diabetes Association 84th Scientific Sessions.
Why Is Arrowhead Pharmaceuticals Stock Trading Higher On Monday? - Arrowhead Pharma ( NASDAQ:ARWR )
On Monday, Arrowhead Pharmaceuticals Inc. ARWR released topline results from the Phase 3 PALISADE study of plozasiran in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome ( FCS ) . FCS is a rare metabolic disease that prevents the body from ...
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday - Stericycle ( NASDAQ:SRCL )
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Monday. Shares of Stericycle, Inc. SRCL rose sharply during Monday's session after the company inked a deal to be acquired by Waste Management Inc. WM for approximately $7.2 billion, including debt.
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates - Athira Pharma ( NASDAQ:ATHA )
Topline data from Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's disease expected in second half of 2024 Submitted Investigational New Drug application to U.S. Food and Drug Administration for ATH-1105 for the treatment of amyotrophic ...
Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment - Amgen ( NASDAQ:AMGN )
Amgen Inc. AMGN reported first-quarter financial results after the closing bell Thursday. Here's a look at the highlights. The Details: Amgen reported quarterly earnings of $3.96 per share, which beat the analyst consensus estimate of $3.87 by 2.33%.
NetApp, Zoom Video And 2 Other Stocks Insiders Are Selling - Arrowhead Pharma ( NASDAQ:ARWR ) , Affirm Holdings ( NASDAQ:AFRM )
The Nasdaq 100 closed higher by around 0.2% on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced.
EQT, Genie Energy And Other Big Stocks Moving Lower On Monday - EQT ( NYSE:EQT )
U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday. Shares of EQT Corporation EQT fell sharply during Monday's session after the company announced that it entered into a definitive merger agreement to acquire Equitrans Midstream. EQT shares fell 8.4% to ...
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday - NetApp ( NASDAQ:NTAP ) , Cooper Companies ( NASDAQ:COO ) , Dell Technologies ( NYSE:DELL )
U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday. Shares of The Cooper Companies, Inc. COO rose sharply during Friday's session after the company reported better-than-expected first-quarter financial results and raised guidance.
There's A Problem With Today's Obesity Drugs - How These Companies Are Solving It
Weight-Loss Drugs: How Outliers Like Biohaven, Regeneron Are Taking On The Muscle Dilemma In The Obesity Space Investor's Business Daily ...
Alpha-1 Antitrypsin Deficiency Market to Register Incremental Growth by 2032, Assesses DelveInsight | Key Companies - Kamada Pharmaceuticals, Arrowhead Pharmaceuticals, Takeda, Mereo BioPharma, AstraZeneca, Inhibrx, Novo Nordisk
Alpha-1 Antitrypsin Deficiency Market to Register Incremental Growth by 2032, Assesses DelveInsight | Key ... PR ...
Top 5 Life Science ETFs
Taking a position in a life science exchange-traded fund ( ETF ) provides exposure to a basket of stocks focused on the healthcare sector, while mitigating the risks of holding shares in a single company.
How To Buy Hot And Promising - But Uncertain - Biotech Stocks
A mix of choppy or nonexistent earnings alongside the promise of game-changing breakthroughs make biotech stocks a challenge for investors. The SPDR S&P Biotech ETF ( XBI ) , now on the IBD Leaderboard watchlist, offers an alternative to betting on a single biotech name.
It's Been An Abysmal Two Years. But Biotech Is Looking Up.
Biotech Stocks, Pharma Heat Up In 2024 As Buyouts, Obesity And AI Drive Excitement Investor's Business Daily ...
Lamb Weston Posts Upbeat Results, Joins Omega Therapeutics, Allstate And Other Big Stocks Moving Higher On Thursday - Allstate ( NYSE:ALL ) , Agiliti ( NYSE:AGTI )
U.S. stocks traded mostly higher, with the Dow Jones index gaining around 150 points on Thursday. Shares of Lamb Weston Holdings, Inc. LW rose during Thursday's session following better-than-expected quarterly results. Lamb Weston posted adjusted earnings of $1.45 per share, beating market ...
